Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 6 September 1985:
Vol. 229. no. 4717, pp. 981 - 984
DOI: 10.1126/science.2992092
Prev | Table of Contents | Next

Articles

Science, Vol 229, Issue 4717, 981-984
Copyright © 1985 by American Association for the Advancement of Science

articles

Recombinant vaccinia virus: immunization against multiple pathogens

ME Perkus, A Piccini, BR Lipinskas, and E Paoletti

The coding sequences for the hepatitis B virus surface antigen, the herpes simplex virus glycoprotein D, and the influenza virus hemagglutinin were inserted into a single vaccinia virus genome. Rabbits inoculated intravenously or intradermally with this polyvalent vaccinia virus recombinant produced antibodies reactive to all three authentic foreign antigens. In addition, the feasibility of multiple rounds of vaccination with recombinant vaccinia virus was demonstrated.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Evidence for Protection against Chronic Hepatitis C Virus Infection in Chimpanzees by Immunization with Replicating Recombinant Vaccinia Virus.
J.-W. Youn, Y.-W. Hu, N. Tricoche, W. Pfahler, M. T. Shata, M. Dreux, F.-L. Cosset, A. Folgori, D.-H. Lee, B. Brotman, et al. (2008)
J. Virol. 82, 10896-10905
   Abstract »    Full Text »    PDF »
Potential approach to immunotherapy of chronic lymphocytic leukemia (CLL): enhanced immunogenicity of CLL cells via infection with vectors encoding for multiple costimulatory molecules.
C. Palena, K. A. Foon, D. Panicali, A. G. Yafal, J. Chinsangaram, J. W. Hodge, J. Schlom, and K. Y. Tsang (2005)
Blood 106, 3515-3523
   Abstract »    Full Text »    PDF »
Vaccines with Enhanced Costimulation Maintain High Avidity Memory CTL.
S. Yang, J. W. Hodge, D. W. Grosenbach, and J. Schlom (2005)
J. Immunol. 175, 3715-3723
   Abstract »    Full Text »    PDF »
Human B cells that hyperexpress a triad of costimulatory molecules via avipox-vector infection: an alternative source of efficient antigen-presenting cells.
C. Palena, M. Zhu, J. Schlom, and K.-Y. Tsang (2004)
Blood 104, 192-199
   Abstract »    Full Text »    PDF »
Modified Vaccinia Virus Ankara Recombinants Are as Potent as Vaccinia Recombinants in Diversified Prime and Boost Vaccine Regimens to Elicit Therapeutic Antitumor Responses.
J. W. Hodge, D. J. Poole, W. M. Aarts, A. Gomez Yafal, L. Gritz, and J. Schlom (2003)
Cancer Res. 63, 7942-7949
   Abstract »    Full Text »    PDF »
Differences in Virus-Induced Cell Morphology and in Virus Maturation between MVA and Other Strains (WR, Ankara, and NYCBH) of Vaccinia Virus in Infected Human Cells.
J. C. Gallego-Gomez, C. Risco, D. Rodriguez, P. Cabezas, S. Guerra, J. L. Carrascosa, and M. Esteban (2003)
J. Virol. 77, 10606-10622
   Abstract »    Full Text »    PDF »
Novel Recombinant Parapoxvirus Vectors Induce Protective Humoral and Cellular Immunity against Lethal Herpesvirus Challenge Infection in Mice.
T. Fischer, O. Planz, L. Stitz, and H.-J. Rziha (2003)
J. Virol. 77, 9312-9323
   Abstract »    Full Text »    PDF »
Evaluation of lumpy skin disease virus, a capripoxvirus, as a replication-deficient vaccine vector.
K. Aspden, J.-A. Passmore, F. Tiedt, and A.-L. Williamson (2003)
J. Gen. Virol. 84, 1985-1996
   Abstract »    Full Text »    PDF »
Enhanced Activation of Human T Cells via Avipox Vector-mediated Hyperexpression of a Triad of Costimulatory Molecules in Human Dendritic Cells.
M. Zhu, H. Terasawa, J. Gulley, D. Panicali, P. Arlen, J. Schlom, and K. Y. Tsang (2001)
Cancer Res. 61, 3725-3734
   Abstract »    Full Text »
Attenuated Modified Vaccinia Virus Ankara Can Be Used as an Immunizing Agent under Conditions of Preexisting Immunity to the Vector.
J. C. Ramírez, M. M. Gherardi, D. Rodríguez, and M. Esteban (2000)
J. Virol. 74, 7651-7655
   Abstract »    Full Text »
Insertion sites for recombinant vaccinia virus construction: effects on expression of a foreign protein.
B. E. H. Coupar, P. G. Oke, and M. E. Andrew (2000)
J. Gen. Virol. 81, 431-439
   Abstract »    Full Text »
Effect of virulence on immunogenicity of single and double vaccinia virus recombinants expressing differently immunogenic antigens: antibody-response inhibition induced by immunization with a mixture of recombinants differing in virulence.
L. Kutinová, V. Ludví ková, L. Maresov á, s. Neme cková, J. Broucek, P. Hainz, and V. Vonka (1999)
J. Gen. Virol. 80, 2901-2908
   Abstract »    Full Text »
A Triad of Costimulatory Molecules Synergize to Amplify T-Cell Activation.
J. W. Hodge, H. Sabzevari, A. Gomez Yafal, L. Gritz, M. G. O. Lorenz, and J. Schlom (1999)
Cancer Res. 59, 5800-5807
   Abstract »    Full Text »    PDF »
Vaccine technologies: view to the future.
N. Rabinovich, P McInnes, D. Klein, and B. Hall (1994)
Science 265, 1401-1404
   Abstract »    PDF »
Vaccinia virus: a tool for research and vaccine development.
B Moss (1991)
Science 252, 1662-1667
   Abstract »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)